The pharmaceutical industry in Bangladesh is facing a critical juncture due to a regulatory deadlock over drug pricing, which has far-reaching implications for both patient care and the country's manufacturing sector. This crisis, now spanning nearly two years, has left a significant number of drug manufacturers in limbo, unable to launch life-saving therapies and innovative treatments. The situation is particularly concerning given the industry's role in meeting domestic demand, exporting to over 150 countries, and its status as one of Bangladesh's most globally competitive sectors.
The heart of the issue lies in the Directorate General of Drug Administration's (DGDA) inability to fix prices for new medicines, a process that has been halted since a High Court order last August. This order, prompted by a writ petition from the Consumer Association of Bangladesh (CAB), directed the government to determine the prices of all life-saving medicines under the Drugs and Cosmetics Act, 2023. However, pharmaceutical companies argue that medicine prices should be determined through consultation with manufacturers, not unilaterally by the government.
The impact of this delay is profound. Industry executives report that investments worth crores of taka in product development, manufacturing, and regulatory compliance are stranded, while patients are denied access to newer treatments. The pipeline includes medicines for major depressive disorder, advanced cancers, chronic asthma, liver fibrosis, sickle cell anemia, infertility, chronic kidney disease, and severe fungal infections. This has led to a two-tier healthcare system, where patients who can afford costly imported medicines can access the latest therapies, while most Bangladeshis are left without comparable treatment options.
The situation is further complicated by the fact that even price reductions are on hold. ACI Pharmaceuticals, for instance, applied to reduce the price of TirzepatideINN 2.5mg/0.5mL, a widely used injectable treatment for Type 2 diabetes, but their application remains pending despite repeated follow-ups. This inability to pass on price reductions, despite global price fluctuations, hinders the industry's ability to stay competitive.
DGDA officials acknowledge the problem but cite legal hurdles as the primary cause of the delay. They explain that the pricing mechanism is governed by Section 30 of the Drugs and Cosmetics Act, 2023, but the Drug Control Committee, which grants final approval for new medicines, has not met for nearly two years due to political changes. This has created a major regulatory bottleneck, as the committee has yet to be fully reconstituted following last year's political transition.
The crisis has led to a call for action from industry leaders, who emphasize the need for regulatory certainty. With Bangladesh preparing for graduation from least developed country status in 2026, when many intellectual property flexibilities for generic medicines will gradually disappear, the timing of this deadlock is particularly critical. The industry's ability to expand, invest, and become globally competitive is being compromised, raising concerns about the long-term sustainability of the pharmaceutical sector in Bangladesh.
In conclusion, the drug pricing deadlock in Bangladesh is a complex issue that requires urgent attention. The government must address the regulatory bottlenecks and find a solution that balances the need for affordable medicines with the industry's need for stability and growth. The future of patient care and the pharmaceutical industry in Bangladesh hangs in the balance, and the time to act is now.
